Carnitine for the Treatment of Fatigue in Multiple Sclerosis

INTERVENTION: control: placebo for 8 weeks Intervention 1: intervention group: carnitine 1000mg/d for 8 weeks (tab 500mg, bid). Intervention 2: control: placebo for 8 weeks. intervention group: carnitine 1000mg/d for 8 weeks (tab 500mg, bid) Treatment ‐ Drugs CONDITION: Multiple sclerosis Multiple Sclerosis. ; Multiple sclerosis PRIMARY OUTCOME: Decrease of fatigue(FSS). Timepoint: week 4 and 8. Method of measurement: FSS score. SECONDARY OUTCOME: Drug side effects. Timepoint: 4,8 weeks. Method of measurement: recall. INCLUSION CRITERIA: INCLUSION CRITERIA: definite relapsing‐remitting MS according to McDonald’s criteria? age between18 and 50 years; Expanded Disability Status Scale (EDSS) less than 4.0; MS related fatigue with a Fatigue Severity Scale (FSS)>4; receiving interferon ß therapy for at least one year Exclusion Criteria: symptoms of depression (Beck Depression Criteria‐pc>5); relapse within previous 8 weeks; had received corticosteroids within previous 8 weeks; had received medications affecting MS related fatigue